BF Biosciences Statistics
Total Valuation
BF Biosciences has a market cap or net worth of PKR 13.45 billion. The enterprise value is 13.62 billion.
| Market Cap | 13.45B |
| Enterprise Value | 13.62B |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BF Biosciences has 88.33 million shares outstanding. The number of shares has increased by 37.69% in one year.
| Current Share Class | 88.33M |
| Shares Outstanding | 88.33M |
| Shares Change (YoY) | +37.69% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.91% |
| Float | 25.00M |
Valuation Ratios
The trailing PE ratio is 27.03.
| PE Ratio | 27.03 |
| Forward PE | n/a |
| PS Ratio | 1.95 |
| PB Ratio | 2.79 |
| P/TBV Ratio | 2.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 46.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.91, with an EV/FCF ratio of -2,506.66.
| EV / Earnings | 27.73 |
| EV / Sales | 1.98 |
| EV / EBITDA | 12.91 |
| EV / EBIT | 16.78 |
| EV / FCF | -2,506.66 |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.15 |
| Quick Ratio | 1.08 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.71 |
| Debt / FCF | -332.43 |
| Interest Coverage | 7.60 |
Financial Efficiency
Return on equity (ROE) is 13.47% and return on invested capital (ROIC) is 8.93%.
| Return on Equity (ROE) | 13.47% |
| Return on Assets (ROA) | 6.00% |
| Return on Invested Capital (ROIC) | 8.93% |
| Return on Capital Employed (ROCE) | 12.15% |
| Revenue Per Employee | 12.87M |
| Profits Per Employee | 918,497 |
| Employee Count | 535 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 2.82 |
Taxes
In the past 12 months, BF Biosciences has paid 318.15 million in taxes.
| Income Tax | 318.15M |
| Effective Tax Rate | 39.30% |
Stock Price Statistics
The stock price has decreased by -34.07% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -34.07% |
| 50-Day Moving Average | 155.07 |
| 200-Day Moving Average | 164.12 |
| Relative Strength Index (RSI) | 44.30 |
| Average Volume (20 Days) | 237,390 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BF Biosciences had revenue of PKR 6.88 billion and earned 491.40 million in profits. Earnings per share was 5.64.
| Revenue | 6.88B |
| Gross Profit | 2.76B |
| Operating Income | 811.73M |
| Pretax Income | 809.55M |
| Net Income | 491.40M |
| EBITDA | 1.06B |
| EBIT | 811.73M |
| Earnings Per Share (EPS) | 5.64 |
Balance Sheet
The company has 1.64 billion in cash and 1.81 billion in debt, giving a net cash position of -169.83 million or -1.92 per share.
| Cash & Cash Equivalents | 1.64B |
| Total Debt | 1.81B |
| Net Cash | -169.83M |
| Net Cash Per Share | -1.92 |
| Equity (Book Value) | 4.82B |
| Book Value Per Share | 54.58 |
| Working Capital | 2.36B |
Cash Flow
In the last 12 months, operating cash flow was 291.08 million and capital expenditures -296.52 million, giving a free cash flow of -5.44 million.
| Operating Cash Flow | 291.08M |
| Capital Expenditures | -296.52M |
| Free Cash Flow | -5.44M |
| FCF Per Share | -0.06 |
Margins
Gross margin is 40.08%, with operating and profit margins of 11.79% and 7.14%.
| Gross Margin | 40.08% |
| Operating Margin | 11.79% |
| Pretax Margin | 11.76% |
| Profit Margin | 7.14% |
| EBITDA Margin | 15.33% |
| EBIT Margin | 11.79% |
| FCF Margin | n/a |
Dividends & Yields
BF Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.69% |
| Shareholder Yield | -37.69% |
| Earnings Yield | 3.65% |
| FCF Yield | -0.04% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BF Biosciences has an Altman Z-Score of 4.2 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.2 |
| Piotroski F-Score | 5 |